Oxaliplatin plus oral fluoropyrimidines in colorectal cancer

Clinical Colorectal Cancer

Volumn 4, Issue SUPPL. 1, 2004, Pages

  Grothey, Axel ^a   Goetz, Matthew P ^a  

^a MAYO CLINIC   (United States)

Author keywords

5 Fluorouracil; Capecitabine; Combination chemotherapy; FOLFORI; FOLFOX; Hand foot syndrome

Indexed keywords

CAPECITABINE; CISPLATIN; CYTOTOXIC AGENT; FLUOROPYRIMIDINE; FLUOROURACIL; FOLIC ACID; FOLINIC ACID; IRINOTECAN; METHOTREXATE; OXALIPLATIN; PRODRUG; TEGAFUR; UFT; URACIL; VITAMIN;

ADVANCED CANCER; ALOPECIA; ANEMIA; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CARDIOTOXICITY; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG ABSORPTION; DRUG BINDING; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG POTENTIATION; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; INFECTION; LEUKOPENIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; OUTPATIENT CARE; REVIEW; SENSORY NEUROPATHY; SEPSIS; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 3042725384     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2004.s.006     Document Type: Article

References (34)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistic, 2003. CA Cancer J Clin 2003; 53:5-26.
2. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996; 77:1254-1262.
3. Schmoll HJ, Buchele T, Grothey A, et al. Where do we stand with 5-fluorouracil? Semin Oncol 1999; 26:589-605.
4. Grothey A, Schmoll HJ. New chemotherapy approaches in colorectal cancer. Curr Opin Oncol 2001; 13:275-286.
5. Carmichael J, Popiela T, Radstone D, et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20:3617-3627.
6. Douillard JY, Hoff PM, Skillings JR, et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20:3605-3616.
7. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropy-rimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34:1274-1281.
8. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19:4097-4106.
9. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19:2282-2292.
10. Cassidy J, Twelves C, Van Cutsem E, et al. Firs-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13:566-575.
11. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 2003; 4(suppl 15):5-13.
12. Gamelin E, Gamelin L, et al. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 2002; 29:21-33.
13. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947.
14. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000: 18:136-147.
15. Grothey A, Deschler B, Kroening H, et al. Phaase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs. weekly high-dose 24th 5-FU infusion/FA + oxaliplatin (OXA) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002; 21:129a (abstract #512).
16. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30.
17. Tournigand C, Andre T, Achille E, et al. FOLFIRI Followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-237.
18. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: inherim results of a phase III trial. J Clin Oncol 2003; 21:2059-2069.
19. Bennouna J, Perrier H, Paillot B, et al. Tegafox, a new combination of UFT/LV and oxaliplatin as first line treatment for patients (pts) with non resectable metastatic colorectal cancer (CRC): Results of a completed multicenter phase II trial. Proc Am Soc Clin Oncol 2003; 22:271 (Abstract #1088).
20. Dorta F, Feliú J, Vincent J, et al. Phase II clinical trial with the combination of oxaliplatin-UFT-1, -leucovorin (OXA-UFT-1,LV) for the first line treatment of advanced colorectal cancer (ACC). Preliminary results (Oncopaz Cooperative Group-Spain). Ann Oncol 2000; 11 (suppl 4):50 (Abstract #220P).
21. González-Flores E, Luque R, Valdivia J, et al. Phase II study of bi-weekly oxaliplatin, UFT and leucovorin (OXA-UFT-LV) in pretreated metastatic colorectal cancer (MCRC). Eur J Cancer Suppl 2003; 1:S74 (Abstract #241).
22. Douillard J, Seitz J. A phase I study of oral uracil/tegafur (UFT) plus leucovorin (LV) combined with oxaliplatin in patients with metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 2001; 20:144a (Abstract #572).
23. Rosati G, Cordio S, Blanco G, et al. A phase II trial of oxaliplatin (L-OHP) and UFT/leucovorin (LV) for advanced colorectal cancer (ACC) in elderly patients. Eur J Cancer Suppl 2003; 1:S74 (Abstract #239).
24. DeSantis S, Zeuli M, Di Costanzo F, et al. Oxaliplatin and capecitabine in advanced colorectal cancer: a dose-finding trial. Proc Am Soc Clin Oncol 2001; 20:141a (Abstract #559).
25. Diaz-Rubio E, Evans TR, Tabemero J, et al. Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Ann Oncol 2002; 13:558-565.
26. Grothey A, Jordan K, Kellner O, et al. Randomized phase II trial of capecitabine plus irinotecan (Caplri) vs capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2003; 22:255 (Abstract #1022).
27. Borner MM, Dietrich D, Stupp R, et al. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002; 20:1759-1766.
28. Carreca I, Comella P, Maiorino L, et al. Oral capecitabine plus oxaliplatin (XELOX regimen) in elderly patients with advanced colorectal carcinoma (ACC). Southern Italy Cooperative Oncology Group (SICOG 0108) phase II study. Proc Am Soc Clin Oncol 2003; 22:731 (Abstract #2939).
29. Jordan K, Kellner O, Mueller L, et al. Capecitabine plus irinotecan or oxaliplatin in patients with advanced gastrointestinal tumors - results of a pilot study. Ann Oncol 2003; 13(suppl 5):79 (Abstract #287).
30. Makatsoris T, Papadimitriou C, Karina M, et al. A phase II study of capecitabine and oxaliplatin as first line treatment for advanced colorectal carcinoma (CRC). A Hellenic Cooperative Oncology Group (HeCOG) study. Proc Am Soc Clin Oncol 2003; 22:360 (Abstract #1447).
31. Shields A, Zalupski M, Marshall J, et al. A phase II trial of oxaliplatin and capecitabine in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 2002; 21:143a (Abstract #568).
32. Scheithauer W, Kornek GV, Raderer M, et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003; 21:1307-1312.
33. Zeuli M, Nardoni C, Pino MS, et al. Phase II study of a capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. Ann Oncol 2003;14:1378-1382.
34. Sastre J, Butts C, Cassidy J, et al. Capecitabine-oxaliplatin combination (XELOX), effective 1st line therapy for patients (pts) with metastatic colorectal cancer (MCRC): Survival update of an international phase II trial. Ann Oncol 2002; 13 (Suppl 5):80 (Abstract #288P).